% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • terry_amln terry_amln Jun 2, 2014 8:45 AM Flag

    GHDX @ASCO scores big June 1

    Multiple Studies Presented at ASCO Annual Meeting Demonstrate Unique, Practice-Changing Impact of Oncotype DX to Optimize Cancer Care
    GHDX) today announced results of six studies being presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 - June 3 in Chicago, underscoring the practice-changing value of Oncotype DX in pre-invasive and invasive breast cancer and colon cancer.

    The presentations include the first Oncotype DX DCIS Scoreâ„¢ clinical decision impact study, which showed a 31 percent change in treatment recommendations. Additionally, a direct comparison study of the Oncotype DX breast cancer test and the ROR score confirmed that the assays are not the same and that the information they provide is not equivalent.

29.97+0.06(+0.20%)Oct 27 4:00 PMEDT